OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced on its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.
Orchestra creates AI agents that help biotech companies manage the minutiae of drug-discovery operations, from tracking finances to resolving scheduling issues with clinical trials.
